PharmAust (ASX:PAA) - Executive Chairman, Dr Roger Aston
Executive Chairman, Dr Roger Aston
Sourced: PharmAust
Market Herald logo


Be the first with the news that moves the market
  • Cancer treatment company PharmAust (PAA) is joining the list of companies striving to find a COVID-19 cure
  • The company’s main drug, monepantel, has until now been trialled for cancer treatment in humans and animals
  • However, PharmAust says the anti-cancer action of the drug may be able to treat viral infections as well
  • PharmAust has teamed up with the Walter and Eliza Hall Institue of Medical Research in Melbourne for the studies
  • Early data will be available as early as May 2020
  • PharmAust shares have gained 28.1 per cent today, currently worth 10.3 cents each

Cancer treatment company PharmAust (PAA) is the latest listed entity to toss a hat in the ring for the COVID-19 cure.

The company is teaming up with the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne to test its leading drug candidate, monepantel, on COVID-19 infections.

Until now, the monepantel treatment has been gradually progressing through different phases of clinical trials for cancers in both humans and dogs.

In early March, PharmAust told shareholders it has partnered with the Brisbane Animal Hospital for a Phase II trial to test monepantel in dogs with B cell lymphoma. Human trials have not yet progressed past Phase I.

A change in direction

However, in light of the coronavirus pandemic, PharmAust has made the call to change tack and see how well monepantel performs against viral infections.

The company said the drug has been “extensible evaluated” in its anti-cancer programmes in humans and animals.

“Monepantel’s mechanism of action in cancer may also prove to be beneficial in the treatment of certain viral diseases,” the company told shareholders this morning.

Big names

Conducting the monepantel studies will be Professor Marc Pellegrini from WEHI. According to PharmAust, Professor Marc has received an Australian National Health and Medical Research Council Excellence Award for his work on chronic infections.

Given WEHI is Australia’s oldest medical research institution, PharmAust’s new partners have some strong reputations behind them which bodes well for the monepantel tests.

Moreover, PharmAust will own all intellectual property results and rights that come about from the studies in return for paying WEHI to test its product.

PharmAust Executive Chairman Dr Roger Aston said this is an important project.

“We are delighted to be working with the Walter and Eliza Hall Institute of Medical Research on this timely and important project and delighted that Professor Marc Pellegrini has agreed to be the Investigator,” Dr Roger said.

Shareholders won’t have to wait long to get a feel for how monepantel performs against COVID-19, either. PharmAust Chief Scientific Officer Dr Richard Mollard said preliminary data from the studies will be available as early as May 2020.

PharmAust shares have spiked 28.1 per cent to their highest point since February. At midday trade, shares are worth 10.3 cents each.

PAA by the numbers
More From The Market Herald
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett

" Paradigm Biopharmaceuticals (ASX:PAR) amends clinical trial

Paradigm Biopharmaceuticals (PAR) has made amendments to its clinical trial protocol for knee osteoarthritis treatment.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) completes recruitment for Indian COVID-19 study

ResApp Health (RAP) has completed the recruitment ahead of schedule for its Indian COVID-19 clinical study.
Botanix Pharmaceuticals (ASX:BOT) - President & Executive Chairman, Vince Ippolito

" Botanix Pharmaceuticals (ASX:BOT) progresses clinical programs

Botanix Pharmaceuticals (BOT) progressed a number of clinical programs during the September quarter.
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham

" Recce Pharmaceuticals (ASX:RCE) receives ethics approval to begin R327 trial

Recce Pharmaceuticals (RCE) has received Human Research Ethics Committee (HREC) approval to begin its phase one intravenous (IV) trial of RECCE327 (R327).